[{"id":"5fc95c78-0abd-4ca1-9e8e-6011739ca3e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04284228","created_at":"2021-01-18T20:47:52.551Z","updated_at":"2024-07-02T16:35:23.484Z","phase":"Phase 1/2","brief_title":"Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT","source_id_and_acronym":"NCT04284228","lead_sponsor":"NexImmune Inc.","biomarkers":" HLA-A • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-A • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • NEXI-001"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 02/20/2020","start_date":" 02/20/2020","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-01-15"}]